{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:43:13Z","timestamp":1793108593246,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Immunol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41577-026-01358-3","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:22:01Z","timestamp":1790594521000},"page":"781-783","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["What the \u2018negative space\u2019 tells us about the immunology of multiple sclerosis"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1954-4425","authenticated-orcid":false,"given":"Max","family":"Kaufmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2883-3226","authenticated-orcid":false,"given":"Lars","family":"Fugger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"1358_CR1","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.cell.2025.12.031","volume":"189","author":"H Kim","year":"2026","unstructured":"Kim, H. et al. Myelin antigen capture in the CNS by B cells expressing EBV latent membrane protein 1 leads to demyelinating lesion formation. Cell 189, 603\u2013619.e25 (2026).","journal-title":"Cell"},{"key":"1358_CR2","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41586-026-10310-3","volume":"653","author":"L Morcom","year":"2026","unstructured":"Morcom, L. et al. DNA damage burden causes selective CUX2 neuron loss in neuroinflammation. Nature 653, 809\u2013818 (2026).","journal-title":"Nature"},{"key":"1358_CR3","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41591-025-04014-w","volume":"32","author":"A Abdelhak","year":"2026","unstructured":"Abdelhak, A. et al. Myelin injury precedes axonal injury and symptomatic onset in multiple sclerosis. Nat. Med. 32, 362\u2013368 (2026).","journal-title":"Nat. Med."},{"key":"1358_CR4","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1038\/s41591-025-03625-7","volume":"31","author":"L Klotz","year":"2025","unstructured":"Klotz, L. et al. Broad rim lesions are a new pathological and imaging biomarker for rapid disease progression in multiple sclerosis. Nat. Med. 31, 2016\u20132026 (2025).","journal-title":"Nat. Med."},{"key":"1358_CR5","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa2415988","volume":"392","author":"RJ Fox","year":"2025","unstructured":"Fox, R. J. et al. Tolebrutinib in nonrelapsing secondary progressive multiple sclerosis. N. Engl. J. Med. 392, 1883\u20131892 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1358_CR6","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1016\/S0140-6736(26)00147-9","volume":"407","author":"SL Hauser","year":"2026","unstructured":"Hauser, S. L. et al. Efficacy and safety of a bodyweight\u2013adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials. Lancet 407, 2180\u20132194 (2026).","journal-title":"Lancet"},{"key":"1358_CR7","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1001\/jama.2025.1604","volume":"333","author":"E Thouvenot","year":"2025","unstructured":"Thouvenot, E. et al. High-dose vitamin D in clinically isolated syndrome typical of multiple sclerosis. JAMA 333, 1413\u20131422 (2025).","journal-title":"JAMA"},{"key":"1358_CR8","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1016\/j.cell.2024.05.031","volume":"187","author":"MS Woo","year":"2024","unstructured":"Woo, M. S. et al. STING orchestrates the neuronal inflammatory stress response in multiple sclerosis. Cell 187, 4043\u20134060.e30 (2024).","journal-title":"Cell"},{"key":"1358_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adt5585","volume":"17","author":"EMU Gavilanes","year":"2025","unstructured":"Gavilanes, E. M. U. et al. SV2A-PET imaging uncovers cortical synapse loss in multiple sclerosis. Sci. Transl. Med. 17, eadt5585 (2025).","journal-title":"Sci. Transl. Med."},{"key":"1358_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52444-w","volume":"15","author":"LJ Wagstaff","year":"2024","unstructured":"Wagstaff, L. J. et al. CRISPR-edited human ES-derived oligodendrocyte progenitor cells improve remyelination in rodents. Nat. Commun. 15, 8570 (2024).","journal-title":"Nat. Commun."},{"key":"1358_CR11","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41590-024-01756-6","volume":"25","author":"M Linnerbauer","year":"2024","unstructured":"Linnerbauer, M. et al. The astrocyte-produced growth factor HB-EGF limits autoimmune CNS pathology. Nat. Immunol. 25, 432\u2013447 (2024).","journal-title":"Nat. Immunol."},{"key":"1358_CR12","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.cell.2025.12.046","volume":"189","author":"J Wang","year":"2026","unstructured":"Wang, J. et al. EBV infection and HLA-DR15 jointly drive multiple sclerosis by myelin peptide presentation. Cell 189, 569\u2013584.e14 (2026).","journal-title":"Cell"},{"key":"1358_CR13","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s41586-026-10274-4","volume":"653","author":"A Schmidt","year":"2026","unstructured":"Schmidt, A. et al. Host control of persistent Epstein\u2013Barr virus infection. Nature 653, 444\u2013454 (2026).","journal-title":"Nature"},{"key":"1358_CR14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMra2501195","volume":"395","author":"SL Hauser","year":"2026","unstructured":"Hauser, S. L. Advances in multiple sclerosis. N. Engl. J. Med. 395, 54\u201368 (2026).","journal-title":"N. Engl. J. Med."},{"key":"1358_CR15","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1126\/science.1225244","volume":"338","author":"M Scheffer","year":"2012","unstructured":"Scheffer, M. et al. Anticipating critical transitions. Science 338, 344\u2013348 (2012).","journal-title":"Science"}],"container-title":["Nature Reviews Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01358-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01358-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01358-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:01:57Z","timestamp":1793106117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01358-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1358"],"URL":"https:\/\/doi.org\/10.1038\/s41577-026-01358-3","relation":{},"ISSN":["1474-1733","1474-1741"],"issn-type":[{"value":"1474-1733","type":"print"},{"value":"1474-1741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"28 September 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.G. has received consulting honoraria from ZLB Behring, Baxter, Candid Tx., Talecris and Kyverna. M.K. and L.F. declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}